https://www.selleckchem.com/pr....oducts/4-hydroxytamo
5 months for patients with mutation, and 19.5 months for patients without mutation (P=0.005). Positive expression of as shown by IHC was detected in majority of SRCC samples, which was higher than our intestinal cohort (28% 12.6%, P=0.033). We further explored the correlation between status and drug sensitivity in 4 SRCC cell lines. SNU601 and SNU668, which harbored mutation, were hypersensitive to MEK and mTOR inhibitors than wide type cell lines KATO-III and NUGC-4. Our findings demonstrate that gene plays
Like
Comment
Share
